Elranatamab in R/R Multiple Myeloma
Condition(s):Refractory Multiple Myeloma; Relapse Multiple Myeloma; Multiple MyelomaLast Updated:November 21, 2023Not yet recruiting
Hide Studies Not Open or Pending
Condition(s):Refractory Multiple Myeloma; Relapse Multiple Myeloma; Multiple MyelomaLast Updated:November 21, 2023Not yet recruiting
Condition(s):Relapsed Refractory Multiple Myeloma (RRMM)Last Updated:February 26, 2024Recruiting
Condition(s):Refractory Plasma Cell Myeloma; Recurrent Plasma Cell MyelomaLast Updated:March 15, 2024Completed
Condition(s):Relapsed/ Refractory Multiple MyelomaLast Updated:January 30, 2023Withdrawn
Condition(s):Multiple MyelomaLast Updated:March 15, 2024Recruiting
Condition(s):Relapsed or Refractory Multiple MyelomaLast Updated:March 6, 2024Recruiting
Condition(s):Multiple MyelomaLast Updated:November 18, 2019Completed
Condition(s):Relapsed or Refractory Multiple MyelomaLast Updated:August 18, 2021Recruiting
Condition(s):Multiple MyelomaLast Updated:January 17, 2023Recruiting
Condition(s):Refractory Multiple MyelomaLast Updated:March 6, 2023Recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.